BACKGROUND: Heightened immunogenicity, measured one month after the primary series of pneumococcal conjugate vaccine (PCV), in African children was previously hypothesized to be due to increased rates of nasopharyngeal pneumococcal colonization during early infancy. METHODS: We analyzed the effect of selected vaccine-serotype (6B, 19F and 23F) nasopharyngeal colonization prior to the first PCV dose or when colonized for the first time prior to the second or third (2nd/3rd) PCV dose on serotype quantitative and qualitative antibody responses. RESULTS: Colonization prior to receiving the first PCV was associated with lower geometric mean antibody concentrations (GMCs) one month after the third dose of PCV and six months later to the colonizing-serotype. Colonized infants also had lower geometric mean titers (GMTs) on opsonophagocytosis activity assay (OPA) and a lower proportion had titers ≥ 8 against the colonizing serotypes (19F and 23F) post vaccination. Colonization occurring only prior to the 2nd/3rdPCV dose was also associated with lower GMCs and OPA GMTs to the colonizing-serotype. The effect of colonization with serotypes 19F and 23F prior to PCV vaccination had a greater effect on a lower proportion of colonized infants having OPA titers ≥ 8 than the effect of colonization on the lower proportion with antibody ≥ 0.35 μg/ml. CONCLUSION: Infant nasopharyngeal colonization at any stage before completing the primary series of PCV vaccination was associated with inferior quantitative and qualitative antibody responses to the colonizing-serotype.
BACKGROUND: Heightened immunogenicity, measured one month after the primary series of pneumococcal conjugate vaccine (PCV), in African children was previously hypothesized to be due to increased rates of nasopharyngeal pneumococcal colonization during early infancy. METHODS: We analyzed the effect of selected vaccine-serotype (6B, 19F and 23F) nasopharyngeal colonization prior to the first PCV dose or when colonized for the first time prior to the second or third (2nd/3rd) PCV dose on serotype quantitative and qualitative antibody responses. RESULTS: Colonization prior to receiving the first PCV was associated with lower geometric mean antibody concentrations (GMCs) one month after the third dose of PCV and six months later to the colonizing-serotype. Colonized infants also had lower geometric mean titers (GMTs) on opsonophagocytosis activity assay (OPA) and a lower proportion had titers ≥ 8 against the colonizing serotypes (19F and 23F) post vaccination. Colonization occurring only prior to the 2nd/3rdPCV dose was also associated with lower GMCs and OPA GMTs to the colonizing-serotype. The effect of colonization with serotypes 19F and 23F prior to PCV vaccination had a greater effect on a lower proportion of colonized infants having OPA titers ≥ 8 than the effect of colonization on the lower proportion with antibody ≥ 0.35 μg/ml. CONCLUSION:Infant nasopharyngeal colonization at any stage before completing the primary series of PCV vaccination was associated with inferior quantitative and qualitative antibody responses to the colonizing-serotype.
Authors: F T Cutts; S M A Zaman; G Enwere; S Jaffar; O S Levine; J B Okoko; C Oluwalana; A Vaughan; S K Obaro; A Leach; K P McAdam; E Biney; M Saaka; U Onwuchekwa; F Yallop; N F Pierce; B M Greenwood; R A Adegbola Journal: Lancet Date: 2005 Mar 26-Apr 1 Impact factor: 79.321
Authors: Susan S Huang; Richard Platt; Sheryl L Rifas-Shiman; Stephen I Pelton; Donald Goldmann; Jonathan A Finkelstein Journal: Pediatrics Date: 2005-09 Impact factor: 7.124
Authors: Katherine L O'Brien; Eugene V Millar; Elizabeth R Zell; Melinda Bronsdon; Robert Weatherholtz; Raymond Reid; Jocelyn Becenti; Sheri Kvamme; Cynthia G Whitney; Mathuram Santosham Journal: J Infect Dis Date: 2007-09-17 Impact factor: 5.226
Authors: Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson Journal: JAMA Date: 2007-04-25 Impact factor: 56.272
Authors: C J Gill; V Mwanakasale; M P Fox; R Chilengi; M Tembo; M Nsofwa; V Chalwe; L Mwananyanda; D Mukwamataba; B Malilwe; D Champo; W B Macleod; D M Thea; D H Hamer Journal: J Infect Dis Date: 2008-04-01 Impact factor: 5.226
Authors: George R Siber; Ih Chang; Sherryl Baker; Philip Fernsten; Katherine L O'Brien; Mathuram Santosham; Keith P Klugman; Shabir A Madhi; Peter Paradiso; Robert Kohberger Journal: Vaccine Date: 2007-02-21 Impact factor: 3.641
Authors: Katherine L O'Brien; Jennifer Moisi; Lawrence H Moulton; Dace Madore; Angelia Eick; Ray Reid; Robert Weatherholtz; Eugene Millar; Diana Hu; Jill Hackell; Robert Kohberger; George Siber; Mathuram Santosham Journal: J Infect Dis Date: 2007-05-24 Impact factor: 5.226
Authors: Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre Journal: N Engl J Med Date: 2008-11-20 Impact factor: 91.245
Authors: J L Wynn; L Li; C M Cotten; D L Phelps; S Shankaran; R N Goldberg; W A Carlo; K Van Meurs; A Das; B R Vohr; R D Higgins; B J Stoll; C T D'Angio Journal: J Perinatol Date: 2013-01-31 Impact factor: 2.521
Authors: Carlos G Grijalva; Marie R Griffin; Kathryn M Edwards; John V Williams; Ana I Gil; Héctor Verastegui; Stella M Hartinger; Jorge E Vidal; Keith P Klugman; Claudio F Lanata Journal: Int J Epidemiol Date: 2013-06-14 Impact factor: 7.196
Authors: Alassane Dicko; Olumuyiwa O Odusanya; Abdoulbaki I Diallo; Gaoussou Santara; Amadou Barry; Amagana Dolo; Aminata Diallo; Yetunde A Kuyinu; Omolara A Kehinde; Nancy François; Dorota Borys; Juan P Yarzabal; Marta Moreira; Lode Schuerman Journal: BMC Public Health Date: 2011-11-23 Impact factor: 3.295
Authors: D M Muema; E W Nduati; M Uyoga; M Bashraheil; J A G Scott; L L Hammitt; B C Urban Journal: Clin Exp Immunol Date: 2015-06-10 Impact factor: 4.330
Authors: Amanda Jane Leach; Edward Kim Mulholland; Mathuram Santosham; Paul John Torzillo; Peter McIntyre; Heidi Smith-Vaughan; Nicole Wilson; Beth Arrowsmith; Jemima Beissbarth; Mark D Chatfield; Victor M Oguoma; Paul Licciardi; Sue Skull; Ross Andrews; Jonathan Carapetis; Joseph McDonnell; Vicki Krause; Peter Stanley Morris Journal: Vaccine X Date: 2021-02-15